Am J Pathol
- YU YP, Liu S, Singhi A, Luo JH, et al
Fusion Gene Detection Enhances Clinical Outcome Prediction of Hepatocellular
Carcinoma Through Machine Learning Analyses.
Am J Pathol. 2026 Jul 28:S0002-9440(26)00199.
Anticancer Res
- UCHIHARA N, Tamaki N, Marusawa H, Urawa N, et al
Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint
Inhibitors for Unresectable Hepatocellular Carcinoma.
Anticancer Res. 2026;46:4443-4452.
- SAKAI H, Goto Y, Fukutomi S, Arai S, et al
Minimally Invasive Versus Open Liver Resection for HCC in the Posterosuperior
Segments: A Propensity Score-matched Study.
Anticancer Res. 2026;46:4735-4744.
Biochem Biophys Res Commun
- ZHOU T, Shen L, Ma Y, Mo S, et al
SMURF1-mediated EFEMP1 ubiquitination reverses the resistance of HCC cells to
sorafenib by promoting ferroptosis.
Biochem Biophys Res Commun. 2026;830:154242.
- FANG X, Liang Z, Zhang Z, Tao M, et al
Corrigendum to "Natural exosome-like nanovesicles from Smilax China rhizome
induce mitophagy-dependent ferroptosis in hepatocellular carcinoma via GPX4/ACSL4
axis" [Biochem. Biophys. Res. Commun. 800 (2026) 153270].
Biochem Biophys Res Commun. 2026 Jul 29:154340. doi: 10.1016/j.bbrc.2026.154340.
- LI C, Ke J, Li X, Ji B, et al
Nanotechnology-assisted thermal ablation for hepatocellular carcinoma: Focus on
radiofrequency and microwave ablation.
Biochem Biophys Res Commun. 2026;831:154269.
BMC Cancer
- MOSER C, Lang SA, Mori A, Hellerbrand C, et al
Editorial expression of concern: NMD-1198, a novel tubulin-binding agent reduces
HIF-1alpha and STAT3 activity in human hepatocellular carcinoma (HCC) cells, and
inhibits growth and vascularization in vivo.
BMC Cancer. 2026;26:899.
Cancer
- LAU-MIN KS, Wang J
Where does histotripsy fit into hepatocellular carcinoma care?
Cancer. 2026;132:e70547.
Cancer Res
- LI J, Ren Z, Yao J, Zhao Y, et al
Mechanosensors Collaborate to Regulate DNA Damage Repair in Hepatocellular
Carcinoma.
Cancer Res. 2026 Jul 29. doi: 10.1158/0008-5472.CAN-25-4356.
Clin Res Hepatol Gastroenterol
- LIU Q, Zhang L, Wang Y, Li J, et al
Effect of intermittent fasting on hepatic steatosis in metabolic
dysfunction-associated steatotic liver disease.
Clin Res Hepatol Gastroenterol. 2026;50:102875.
- KANGAS T, Plessier A, Ramier C, Elkrief L, et al
Employment and work absenteeism in individuals living with a vascular liver
disease: a European multicenter study.
Clin Res Hepatol Gastroenterol. 2026;50:102876.
- SUFFERT LC, Pergher EAB, de Abreu HS, Abreu ES, et al
Burden and Distribution of Multidrug-Resistant Bacteria Among Hospitalized
Patients with Cirrhosis: A Systematic Review and Meta-Analysis.
Clin Res Hepatol Gastroenterol. 2026 Jun 30:102877.
- REN R, Wang Z
Safety and efficacy of hepatic arterial infusion chemotherapy combined with
camrelizumab and apatinib for advanced hepatocellular carcinoma: A retrospective
clinical analysis.
Clin Res Hepatol Gastroenterol. 2026;50:102880.
- KAGZI Y, Asif A, Wang Y, Fischer J, et al
Evaluating performance of non-invasive tests for fibrosis detection in MASLD with
Type 2 Diabetes Mellitus: Insights from VCTE-Based assessment.
Clin Res Hepatol Gastroenterol. 2026;50:102879.
- MA X, Huang C, Shi H, Wang Q, et al
Clinical features of anti-gp210-positive, AMA-negative patients with abnormal
liver function.
Clin Res Hepatol Gastroenterol. 2026;50:102846.
- LOWRY ADAMITIS SB, Karnsakul W
Optimizing approach to liver biochemistry abnormalities in cystic fibrosis
pediatrics: Balancing efficiency and risk-benefit.
Clin Res Hepatol Gastroenterol. 2026;50:102849.
- EL BOUKILI I, Habouzit V, Mohamed S, Casteillo F, et al
Selective internal radiation therapy as a bridge to curative-intent surgery in
bulky colorectal liver metastases.
Clin Res Hepatol Gastroenterol. 2026;50:102851.
- SCHMITZ SM, Grunwald BT, Tasdogan A, Heise D, et al
Impact of Metabolic Liver Disease on Colorectal Cancer and Liver Metastases:
Pathophysiology and Implications for Hepatobiliary Surgery.
Clin Res Hepatol Gastroenterol. 2026 May 25:102853.
- CHEN Z, Zhu W, Liu G, Yu B, et al
Integrative Analysis of Genetic and Cellular Interactions Connecting Inflammatory
Bowel Disease and Primary Biliary Cholangitis.
Clin Res Hepatol Gastroenterol. 2026 Jul 14:102885.
- WANG L, Chen J, Lou X, Liu J, et al
Causes of death in patients diagnosed with liver metastasis: a population-based
study.
Clin Res Hepatol Gastroenterol. 2026;50:102883.
- SUN K, Gao Q, Zhang C, Niu H, et al
TACE-induced liver injury in hepatocellular carcinoma: mechanisms, prediction,
and prevention in the era of gut microbiota and inflammasome research.
Clin Res Hepatol Gastroenterol. 2026;50:102874.
- FISCHER SE, van Ruijven B, Kerbert AJC, Fiocco M, et al
Dipstick urinary chloride as a surrogate marker of urinary sodium in cirrhosis: a
prospective multicenter pilot study.
Clin Res Hepatol Gastroenterol. 2026 Jun 16:102871.
- DIAZ I, Ahmad S, Souza M
Primary hypobetalipoproteinemia as a specific etiology of steatotic liver
disease: A meta-analysis.
Clin Res Hepatol Gastroenterol. 2026;50:102863.
Endoscopy
- HU SS, Liu WH
Contrast-harmonic endoscopic ultrasound-assisted endoscopic ultrasound-guided
hepaticogastrostomy for minimally dilated intrahepatic ducts.
Endoscopy. 2026 Jul 31. doi: 10.1055/a-2908-4930.
Gut
- TAVABIE O, Crisp H, Griffiths C, Allen R, et al
A patient-driven agenda for liver cirrhosis research.
Gut. 2026 Jul 27:gutjnl-2026-339715. doi: 10.1136/gutjnl-2026-339715.
- YANG G, Gou L, Liu X, Xu C, et al
Galectin-14, a primate-specific oncofetal protein, impairs anti-tumour immunity
in hepatocellular carcinoma by driving elevated heparan sulphate modification.
Gut. 2026 Jul 28:gutjnl-2026-338068. doi: 10.1136/gutjnl-2026-338068.
- PIECHA F, Al Jawazneh A, Buescher G, Harberts A, et al
Decompression of portal hypertension by transjugular intrahepatic portosystemic
shunt reverses markers of gut barrier dysfunction and cirrhosis-associated immune
dysfunction.
Gut. 2026 Jul 30:gutjnl-2026-338318. doi: 10.1136/gutjnl-2026-338318.
- YANG TC, Ha NB, Fan B, Barry F, et al
Rate and clinical predictors of skeletal muscle loss in patients with cirrhosis.
Gut. 2026 Jul 30:gutjnl-2026-339159. doi: 10.1136/gutjnl-2026-339159.
- D'ALESSIO A, Wong CC
Clonal evolution driving timing and sites of postsurgical recurrences in
hepatocellular carcinoma.
Gut. 2026 Jul 31:gutjnl-2026-339683. doi: 10.1136/gutjnl-2026-339683.
J Clin Oncol
- LEVI ST, Barkun J, McCulloch P, Odisio BC, et al
Histotripsy and the IDEAL Framework: A Clarion Call for the Responsible and
Evidence-Based Application of New Technology.
J Clin Oncol. 2026;44:2075-2078.
J Gastroenterol
- FAN Z, Li L
Comment on "Intestinal obstruction impairs the antitumor function of hepatic
natural killer cells against colorectal cancer".
J Gastroenterol. 2026 Jul 28. doi: 10.1007/s00535-026-02490.
- YASUDA K, Iida N, Takeshita Y, Masuo Y, et al
Tofogliflozin alters amino acid metabolism in gut microbiota linked to hepatic
transcriptomic signatures in MASLD.
J Gastroenterol. 2026 Jul 30. doi: 10.1007/s00535-026-02488.
J Hepatol
- CHAN SL, Sangro B, Rimassa L
The hepatocellular carcinoma wish list: Five aspirations for future care.
J Hepatol. 2026 Jul 25:S0168-8278(26)02705-4. doi: 10.1016/j.jhep.2026.
- ENGELMANN C, Verma N, Qi T, Catharina Kerbert AJ, et al
Corrigendum to "Development and validation of the A-TANGO organ failure score for
acute-on-chronic liver failure in global cohorts" [J Hepatol 85 (2026) 91-105].
J Hepatol. 2026 Jul 25:S0168-8278(26)02713-3. doi: 10.1016/j.jhep.2026.
- CASTILLO E, Felber M, Paule L, Juanola O, et al
Non-selective beta-blockers reduce bacterial translocation by restoring gut barrier
function during experimental cirrhosis.
J Hepatol. 2026 Jul 28:S0168-8278(26)02747-9. doi: 10.1016/j.jhep.2026.
- BHOORI S, Rivoltini L, Leoncini G, Sioli V, et al
Revisiting rejection after immune checkpoint inhibitor exposure prior to liver
transplantation for hepatocellular carcinoma: Reply to: "Rejection and
perioperative management in liver transplantation following immune checkpoint
inhibitor-based downsta
J Hepatol. 2026 Jul 30:S0168-8278(26)02749-2. doi: 10.1016/j.jhep.2026.
- GUO Z, Zhao Q, Jia Z, Huang C, et al
Corrigendum to: "A randomized-controlled trial of ischemia-free liver
transplantation for end-stage liver disease" [J Hepatol 79 (2023) 394-402].
J Hepatol. 2026 Jul 30:S0168-8278(26)02711-X. doi: 10.1016/j.jhep.2026.
J Pediatr Surg
- TIAN Y, Chen X, Ye M, Xiao P, et al
Prospective Comparison of Near-Infrared I and II Fluorescence Imaging for
Intraoperative Navigation in Pediatric Hepatoblastoma Resection.
J Pediatr Surg. 2026 Jul 30:163340. doi: 10.1016/j.jpedsurg.2026.163340.
Oncogene
- HUANG H, Huang C, Yang P, Xian S, et al
The epigenetic KMT5C-HDAC1 axis promotes hepatocellular carcinoma stemness and
progression through SERPINA4 repression and chromatin compaction.
Oncogene. 2026 Jul 27. doi: 10.1038/s41388-026-03920.
PLoS One
- GU K, Kang TW, Shin J, Sinn DH, et al
Prognostic factors in first-line atezolizumab-bevacizumab treatment of
intermediate or advanced hepatocellular carcinoma.
PLoS One. 2026;21:e0354176.
Radiol Imaging Cancer
- SIDDIQI NS
Intratumoral Therapy with or without Pulsed Electric Field Ablation for
Hepatocellular Carcinoma: A Proof-of-Concept Study.
Radiol Imaging Cancer. 2026;8:e269017.
Transplant Proc
- MARIN-CASTRO P, Pinheiro RS, Waisberg DR, Arantes RM, et al
Profile of Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
at a Brazilian High-Complexity Referral Center: Tumor Biology as a Predictor of
Post-Transplant Recurrence.
Transplant Proc. 2026 Jul 31:S0041-1345(26)00358.
Transplantation
- CALTHORPE LM, Lee C, Fenton C, Barron G, et al
The Activity Measure for Postacute Care "6-Clicks" Basic Mobility Score is
Associated with Pre- and Posttransplant Mortality in Hospitalized Patients with
Cirrhosis.
Transplantation. 2026 Jul 30. doi: 10.1097/TP.0000000000005855.
- QUINTERO-BERNABEU J, Salcedo-Allende MT, Juamperez-Goni J, Mercadal-Hally M, et al
Follow-up Liver Biopsy as a Tool for Tailoring Immunosuppressive Treatment in
Pediatric Liver Transplantation.
Transplantation. 2026 Apr 27. doi: 10.1097/TP.0000000000005721.
- TANAKA T, Lai JC, Axelrod D
Incorporating Model for End-stage Liver Disease Trajectories into Liver
Allocation.
Transplantation. 2026;110:e1687-e1694.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016